PF-Atlas › Clinical Trials › NCT04668235

Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients

AZVUDINE · Phase 3

Registry ID

NCT04668235

Phase

Phase 3

Status

Completed

Drug / intervention

AZVUDINE

Sponsor

HRH Pharmaceuticals Limited

Start

2021-04-23

About this trial

AZVUDINE is evaluated in NCT04668235, a Phase 3 idiopathic pulmonary fibrosis study sponsored by HRH Pharmaceuticals Limited. Current status: Completed.

View NCT04668235 on ClinicalTrials.gov →

Explore related

All AZVUDINE trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT04668235 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.